Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
Date
2009-10Author
Walker, LM
Phogat, SK
Chan-Hui, PY
Wagner, D
Phung, P
Goss, JL
Wrin, T
Simek, MD
Fling, S
Mitcham, JL
Lehrman, JK
Priddy, FH
Olsen, OA
Frey, SM
Hammond, PW
Protocol G Principal Investigators
Kaminsky, S
Zamb, T
Moyle, M
Koff, WC
Poignard, P
Burton, DR
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals, define critical epitopes for HIV vaccine design. Using a systematic approach, we have examined neutralization breadth in the sera of about 1800 HIV-1-infected individuals, primarily infected with non-clade B viruses, and have selected donors for monoclonal antibody (mAb) generation. We then used a high-throughput neutralization screen of antibody-containing culture supernatants from about 30,000 activated memory B cells from a clade A-infected African donor to isolate two potent mAbs that target a broadly neutralizing epitope. This epitope is preferentially expressed on trimeric Envelope protein and spans conserved regions of variable loops of the gp120 subunit. The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses.
URI
mwww.ncbi.nlm.nih.gov/whalecom0/pubmed/19729618http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/32413
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335270/
Citation
Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3Publisher
University of Nairobi School of medicine,University of Nairobi Department of Immunology and Microbial Science
Collections
- Faculty of Health Sciences (FHS) [10387]